Covered recipient · General Payments record
JAY A SHAH
Allopathic & Osteopathic Physicians Internal Medicine Nephrology
General Payments · PY2019–2024
$1,361.71
- Reported across 43 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $244.09 | 10 |
| Education | $24.61 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Relypsa, Inc. | $85.90 | 3 |
| Amgen Inc. | $48.27 | 2 |
| Retrophin, Inc. | $41.58 | 2 |
| AKEBIA THERAPEUTICS INC | $24.61 | 1 |
| Ardelyx, Inc. | $24.43 | 1 |
| Fresenius USA Marketing, Inc. | $23.94 | 1 |
| Acerta Pharma LLC | $19.97 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (11)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| AKEBIA THERAPEUTICS INC | $24.61 | 08/06/2024 | Education | Undisputed | 01/23/2026 | 1145832639 | CMS |
| Amgen Inc. | $29.95 | 05/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117379898 | CMS |
| Amgen Inc. | $18.32 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117379900 | CMS |
| Ardelyx, Inc. | $24.43 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146706989 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.97 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105546123 | CMS |
| Fresenius USA Marketing, Inc. | $23.94 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154194530 | CMS |
| Travere Therapeutics, Inc. | $24.03 | 01/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149928358 | CMS |
| Travere Therapeutics, Inc. | $17.55 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149928354 | CMS |
| Vifor Pharma, Inc. | $34.35 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124033666 | CMS |
| Vifor Pharma, Inc. | $30.09 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124047177 | CMS |
| Vifor Pharma, Inc. | $21.46 | 07/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124057621 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.